BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-7.42%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$5.38B
AUM Growth
+$5.38B
(-8.2%)
Cap. Flow
+$102M
Cap. Flow
% of AUM
1.9%
Top 10 Holdings %
Top 10 Hldgs %
41.73%
Holding
223
New
22
Increased
133
Reduced
36
Closed
13
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$21.9M |
| 2 |
Glaukos
GKOS
|
$18.4M |
| 3 |
Arvinas
ARVN
|
$17.4M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$14.4M |
| 5 |
Becton Dickinson
BDX
|
$12.9M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$75.9M |
| 2 |
Gilead Sciences
GILD
|
$32.8M |
| 3 |
Neurocrine Biosciences
NBIX
|
$22.3M |
| 4 |
Teladoc Health
TDOC
|
$20M |
| 5 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$15.8M |
Sector Composition
| 1 | Healthcare | 94.28% |
| 2 | Industrials | 0.53% |
| 3 | Technology | 0.51% |
| 4 | Financials | 0.07% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Align Technology
ALGN
$10.3B
| $61.2M | 1.14% | 338,483 +31,888 | +10% | +$5.77M |
|
27
Nektar Therapeutics
NKTR
$568M
| $57.8M | 1.07% | 3,172,886 +540,200 | +21% | +$9.84M |
|
28
Boston Scientific
BSX
$156B
| $57.8M | 1.07% | 1,419,988 +39,206 | +3% | +$1.6M |
|
29
Danaher
DHR
$147B
| $53.7M | 1% | 371,763 +21,065 | +6% | +$3.04M |
|
30
UnitedHealth
UNH
$281B
| $51.9M | 0.96% | 238,712 +44,318 | +23% | +$9.63M |
|
|
31
Becton Dickinson
BDX
$55.3B
| $50.8M | 0.94% | 200,827 +51,135 | +34% | +$12.9M |
|
|
AKCA
32
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $47.9M | 0.89% | 3,109,911 +9,143 | +0.3% | +$141K |
|
33
Bristol-Myers Squibb
BMY
$96B
| $47.5M | 0.88% | 937,009 +81,400 | +10% | +$4.13M |
|
|
ICPT
34
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $46.6M | 0.87% | 702,176 -9,627 | -1% | -$639K |
|
35
Voyager Therapeutics
VYGR
$186M
| $46.5M | 0.87% | 2,704,683 +24,400 | +0.9% | +$420K |
|
36
Edwards Lifesciences
EW
$47.8B
| $42.8M | 0.8% | 194,432 +20,466 | +12% | +$4.5M |
|
37
Jazz Pharmaceuticals
JAZZ
$7.75B
| $42.3M | 0.79% | 330,227 -1,946 | -0.6% | -$249K |
|
38
Stryker
SYK
$150B
| $40.7M | 0.76% | 188,284 +29,121 | +18% | +$6.3M |
|
|
BOLD
39
DELISTED
Audentes Therapeutics, Inc
BOLD
| $40.2M | 0.75% | 1,429,604 +60,000 | +4% | +$1.69M |
|
40
Cigna
CI
$80.3B
| $36.3M | 0.68% | 239,294 +28,540 | +14% | +$4.33M |
|
|
41
Gilead Sciences
GILD
$140B
| $35M | 0.65% | 551,600 -517,600 | -48% | -$32.8M |
|
42
CRISPR Therapeutics
CRSP
$4.71B
| $34.3M | 0.64% | 837,162 +26,700 | +3% | +$1.09M |
|
43
Sangamo Therapeutics
SGMO
$157M
| $33M | 0.61% | 3,650,000 | – | – |
|
44
Wave Life Sciences
WVE
$1.53B
| $31.9M | 0.59% | 1,552,858 +37,856 | +2% | +$777K |
|
45
Baxter International
BAX
$12.7B
| $31.1M | 0.58% | 355,568 +41,331 | +13% | +$3.62M |
|
46
Centene
CNC
$14.3B
| $30M | 0.56% | 692,914 +18,389 | +3% | +$795K |
|
47
Q32 Bio
QTTB
$20.9M
| $29.2M | 0.54% | 1,612,122 +210,000 | +15% | +$3.8M |
|
48
HCA Healthcare
HCA
$94.5B
| $25.5M | 0.47% | 211,382 +24,637 | +13% | +$2.97M |
|
49
DexCom
DXCM
$29.5B
| $25.2M | 0.47% | 168,887 +3,751 | +2% | +$560K |
|
|
50
Glaukos
GKOS
$5.5B
| $25.1M | 0.47% | 402,148 +294,913 | +275% | +$18.4M |
|